Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000432647

Medchemexpress LLC Pizotifen | 15574-96-6 | MFCD00864192 | 99.6% | C19H21NS | 200 MG
SDP

Catalog No. 5000432647
Encompass_Preferred

Pizotifen, also known as Pizotyline, is a potent 5-HT2 receptor antagonist with high affinity for the 5-HT1C binding site. It is also recognized for its antidepressant properties, specifically as a 5-HT2A receptor antagonist.

  • Acts as a potent 5-HT2 receptor antagonist.
  • Shows strong affinity for the 5-HT1C binding site.
  • Functions as an antidepressant 5-HT2A receptor antagonist.
  • Capable of inhibiting serotonin-enhanced ADP-induced platelet aggregation.
  • Studies have shown no significant differences in implantations, live, dead fetuses, resorptions, or the occurrence of external, skeletal, and visceral anomalies compared to control groups.
  • No significant differences in chromosome aberrations in bone marrow cells of treated mice.
  • No elevation in micronuclei frequency in the micronucleus test.

Catalog No. 50-004-32647 Supplier Medchemexpress LLC Supplier No. HYB0115200MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Pizotifen, also known as Pizotyline, is a potent 5-HT2 receptor antagonist with high affinity for the 5-HT1C binding site. It is also recognized for its antidepressant properties, specifically as a 5-HT2A receptor antagonist.

  • Acts as a potent 5-HT2 receptor antagonist.
  • Shows strong affinity for the 5-HT1C binding site.
  • Functions as an antidepressant 5-HT2A receptor antagonist.
  • Capable of inhibiting serotonin-enhanced ADP-induced platelet aggregation.
  • Studies have shown no significant differences in implantations, live, dead fetuses, resorptions, or the occurrence of external, skeletal, and visceral anomalies compared to control groups.
  • No significant differences in chromosome aberrations in bone marrow cells of treated mice.
  • No elevation in micronuclei frequency in the micronucleus test.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.